Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Nonpharmacological Treatment for Nontuberculous Mycobacterial Pulmonary Disease

  • Hyung-Jun Kim (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital)
  • Received : 2024.03.08
  • Accepted : 2024.04.24
  • Published : 2024.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Nontuberculous mycobacterial pulmonary disease (NTM-PD) results from the exposure of susceptible hosts to a diverse group of environmental mycobacteria. The emphasis on nonpharmacological strategies is motivated by the widespread presence of NTM in various environments, and the inconsistent success rates of pharmacological treatments. Modifiable factors contributing to NTM-PD development include impaired airway clearance, low body mass index, gastroesophageal reflux disease, and exposure to NTM habitats. This suggests that lifestyle and environmental modifications could affect disease development and progression. The review highlights several modalities that can modify the risk factors. Airway clearance techniques, informed by the "gel-on-brush" model of the bronchial epithelium, aim to enhance mucociliary clearance, and have the potential to alleviate symptoms and improve lung function. The impact of nutritional status is also examined, with a lower body mass index linked to an increased risk and progression of NTM-PD, indicating the importance of targeted nutritional support. Additionally, the theoretical and epidemiological links between gastroesophageal reflux disease and NTM-PD advocate careful management of reflux episodes. Understanding the risk of NTM transmission through environmental exposure to contaminated water and soil is also crucial. Strategies to mitigate this risk, including effective water management and minimizing soil contact, are presented as vital preventive measures. The review supports the inclusion of nonpharmacological treatments within a comprehensive NTM-PD management strategy, alongside conventional pharmacological therapies. This integrated approach seeks to improve the overall understanding and handling of NTM-PD.

Keywords

References

  1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
  2. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 2020;71:e1-36.
  3. Honda JR, Virdi R, Chan ED. Global environmental nontuberculous mycobacteria and their contemporaneous man-made and natural niches. Front Microbiol 2018;9:2029.
  4. Ratnatunga CN, Lutzky VP, Kupz A, Doolan DL, Reid DW, Field M, et al. The rise of non-tuberculosis mycobacterial lung disease. Front Immunol 2020;11:303.
  5. Macovei L, McCafferty J, Chen T, Teles F, Hasturk H, Paster BJ, et al. The hidden 'mycobacteriome' of the human healthy oral cavity and upper respiratory tract. J Oral Microbiol 2015;7:26094.
  6. Matsuyama M, Matsumura S, Nonaka M, Nakajima M, Sakai C, Arai N, et al. Pathophysiology of pulmonary nontuberculous mycobacterial (NTM) disease. Respir Investig 2023;61:135-48.
  7. Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R, Hasegawa N, et al. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J 2019;54:1801991.
  8. Kwak N, Park J, Kim E, Lee CH, Han SK, Yim JJ. Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis. Clin Infect Dis 2017;65:1077-84.
  9. Ku JH, Henkle E, Aksamit TR, Barker A, Brunton AE, Winthrop KL, et al. Treatment of nontuberculous mycobacterial (NTM) pulmonary infection in the US bronchiectasis and NTM Registry: treatment patterns, adverse events, and adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines. Clin Infect Dis 2023;76:338-41.
  10. Kim JY, Park J, Choi Y, Kim TS, Kwak N, Yim JJ. Microbiological cure at treatment completion is associated with longer survival in patients with Mycobacterium avium complex pulmonary disease. Chest 2023;164:1108-14.
  11. Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis 2016;45:123-34.
  12. van Ingen J, Bendien SA, de Lange WC, Hoefsloot W, Dekhuijzen PN, Boeree MJ, et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen- Arnhem region, The Netherlands. Thorax 2009;64:502-6.
  13. Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, et al. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 2006;129:341-8.
  14. Hwang JA, Kim S, Jo KW, Shim TS. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course. Eur Respir J 2017;49:1600537.
  15. Jo KW, Park YE, Chong YP, Shim TS. Spontaneous sputum conversion and reversion in Mycobacterium abscessus complex lung disease. PLoS One 2020;15:e0232161.
  16. Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 2017;72(Suppl 2):ii1-64.
  17. Kim Y, Yoon JH, Ryu J, Yang B, Chung SJ, Kang HK, et al. Gastroesophageal reflux disease increases susceptibility to nontuberculous mycobacterial pulmonary disease. Chest 2023;163:270-80.
  18. Loebinger MR, Quint JK, van der Laan R, Obradovic M, Chawla R, Kishore A, et al. Risk factors for nontuberculous mycobacterial pulmonary disease: a systematic literature review and meta-analysis. Chest 2023;164:1115-24.
  19. Rosain J, Kong XF, Martinez-Barricarte R, Oleaga-Quintas C, Ramirez-Alejo N, Markle J, et al. Mendelian susceptibility to mycobacterial disease: 2014-2018 update. Immunol Cell Biol 2019;97:360-7.
  20. Song JH, Kim BS, Kwak N, Han K, Yim JJ. Impact of body mass index on development of nontuberculous mycobacterial pulmonary disease. Eur Respir J 2021;57:2000454.
  21. Button B, Cai LH, Ehre C, Kesimer M, Hill DB, Sheehan JK, et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 2012;337:937-41.
  22. Ramsey KA, Chen AC, Radicioni G, Lourie R, Martin M, Broomfield A, et al. Airway mucus hyperconcentration in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2020;201:661-70.
  23. Button B, Boucher RC; University of North Carolina Virtual Lung Group. Role of mechanical stress in regulating airway surface hydration and mucus clearance rates. Respir Physiol Neurobiol 2008;163:189-201.
  24. Button BM, Button B. Structure and function of the mucus clearance system of the lung. Cold Spring Harb Perspect Med 2013;3:a009720.
  25. Herrero-Cortina B, Spinou A, Oliveira A, O'Neill B, Jacome C, Dal Corso S, et al. Airway clearance techniques and exercise in people with bronchiectasis: two different coins. Eur Respir J 2023;62:2300741.
  26. Coppolo DP, Schloss J, Suggett JA, Mitchell JP. Non-pharmaceutical techniques for obstructive airway clearance focusing on the role of oscillating positive expiratory pressure (OPEP): a narrative review. Pulm Ther 2022;8:1-41.
  27. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34:1086-92.
  28. Basavaraj A, Segal L, Samuels J, Feintuch J, Feintuch J, Alter K, et al. Effects of chest physical therapy in patients with non-tuberculous mycobacteria. Int J Respir Pulm Med 2017;4:065.
  29. Kim HJ, Kwak N, Hong H, Kang N, Im Y, Jhun BW, et al. BACES score for predicting mortality in nontuberculous mycobacterial pulmonary disease. Am J Respir Crit Care Med 2021;203:230-6.
  30. Kartalija M, Ovrutsky AR, Bryan CL, Pott GB, Fantuzzi G, Thomas J, et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med 2013;187:197-205.
  31. Hong JY, Yang GE, Ko Y, Park YB, Sim YS, Park SH, et al. Changes in cholesterol level correlate with the course of pulmonary nontuberculous mycobacterial disease. J Thorac Dis 2016;8:2885-94.
  32. Chan ED, Iseman MD. Slender, older women appear to be more susceptible to nontuberculous mycobacterial lung disease. Gend Med 2010;7:5-18.
  33. Martin-Romero C, Santos-Alvarez J, Goberna R, Sanchez- Margalet V. Human leptin enhances activation and proliferation of human circulating T lymphocytes. Cell Immunol 2000;199:15-24.
  34. Tasaka S, Hasegawa N, Nishimura T, Yamasawa W, Kamata H, Shinoda H, et al. Elevated serum adiponectin level in patients with Mycobacterium avium-intracellulare complex pulmonary disease. Respiration 2010;79:383-7.
  35. Olveira G, Olveira C, Dona E, Palenque FJ, Porras N, Dorado A, et al. Oral supplement enriched in HMB combined with pulmonary rehabilitation improves body composition and health related quality of life in patients with bronchiectasis (Prospective, Randomised Study). Clin Nutr 2016;35:1015-22.
  36. Bhargava A, Bhargava M, Meher A, Teja GS, Velayutham B, Watson B, et al. Nutritional support for adult patients with microbiologically confirmed pulmonary tuberculosis: outcomes in a programmatic cohort nested within the RATIONS trial in Jharkhand, India. Lancet Glob Health 2023;11:e1402-11.
  37. Youssefnia A, Pierre A, Hoder JM, MacDonald M, Shaffer MJB, Friedman J, et al. Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review. J Thorac Dis 2022;14:3575-97.
  38. Kubala J, Gunnars K. 16 Delicious high protein foods [Internet]. San Francisco: Healthline; 2023 [cited 2024 May 3]. Available from: https://www.healthline.com/nutrition/high-protein-foods.
  39. Dawrs SN, Kautz M, Chan ED, Honda JR. Mycobacterium abscessus and gastroesophageal reflux: an in vitro study. Am J Respir Crit Care Med 2020;202:466-9.
  40. Falkinham JO 3rd. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol 2009;107:356-67.
  41. Bodmer T, Miltner E, Bermudez LE. Mycobacterium avium resists exposure to the acidic conditions of the stomach. FEMS Microbiol Lett 2000;182:45-9.
  42. Thomson RM, Armstrong JG, Looke DF. Gastroesophageal reflux disease, acid suppression, and Mycobacterium avium complex pulmonary disease. Chest 2007;131:1166-72.
  43. Kahrilas PJ. Clinical practice: gastroesophageal reflux disease. N Engl J Med 2008;359:1700-7.
  44. Falkinham JO 3rd. Ecology of nontuberculous mycobacteria: where do human infections come from? Semin Respir Crit Care Med 2013;34:95-102.
  45. Adjemian J, Olivier KN, Seitz AE, Falkinham JO 3rd, Holland SM, Prevots DR. Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am J Respir Crit Care Med 2012;186:553-8.
  46. Maekawa K, Ito Y, Hirai T, Kubo T, Imai S, Tatsumi S, et al. Environmental risk factors for pulmonary Mycobacterium avium-intracellulare complex disease. Chest 2011;140:723-9.
  47. Yoon JK, Kim TS, Kim JI, Yim JJ. Whole genome sequencing of nontuberculous Mycobacterium (NTM) isolates from sputum specimens of co-habiting patients with NTM pulmonary disease and NTM isolates from their environment. BMC Genomics 2020;21:322.
  48. Tzou CL, Dirac MA, Becker AL, Beck NK, Weigel KM, Meschke JS, et al. Association between Mycobacterium avium complex pulmonary disease and mycobacteria in home water and soil. Ann Am Thorac Soc 2020;17:57-62.
  49. Park Y, Kwak SH, Yong SH, Lee SH, Leem AY, Kim SY, et al. The association between behavioral risk factors and nontuberculous mycobacterial pulmonary disease. Yonsei Med J 2021;62:702-7.
  50. Prevots DR, Adjemian J, Fernandez AG, Knowles MR, Olivier KN. Environmental risks for nontuberculous mycobacteria: individual exposures and climatic factors in the cystic fibrosis population. Ann Am Thorac Soc 2014;11:1032-8.
  51. Falkinham JO 3rd. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis 2011;17:419-24.
  52. Guenette S, Williams MD, Falkinham JO 3rd. Growth temperature, trehalose, and susceptibility to heat in Mycobacterium avium. Pathogens 2020;9:657.
  53. Rodgers MR, Blackstone BJ, Reyes AL, Covert TC. Colonisation of point of use water filters by silver resistant non-tuberculous mycobacteria. J Clin Pathol 1999;52:629.
  54. Cerna-Cortes JF, Cortes-Cueto AL, Villegas-Martinez D, Leon-Montes N, Salas-Rangel LP, Rivera-Gutierrez S, et al. Bacteriological quality of bottled water obtained from Mexico City small water purification plants: incidence and identification of potentially pathogenic nontuberculous mycobacteria species. Int J Food Microbiol 2019;306:108260.